NO20075804L - Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel - Google Patents

Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel

Info

Publication number
NO20075804L
NO20075804L NO20075804A NO20075804A NO20075804L NO 20075804 L NO20075804 L NO 20075804L NO 20075804 A NO20075804 A NO 20075804A NO 20075804 A NO20075804 A NO 20075804A NO 20075804 L NO20075804 L NO 20075804L
Authority
NO
Norway
Prior art keywords
indazole derivative
retinal neuronal
retinal
nerve cell
agent
Prior art date
Application number
NO20075804A
Other languages
English (en)
Inventor
Atsushi Shimazaki
Hisayuki Seike
Takeshi Matsugi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of NO20075804L publication Critical patent/NO20075804L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Som et resultat av intense studier for formålet å finne en ny medisinsk anvendelse av et indazolderivat, ble det funnet at et indazolderivat inhiberer glutamat-indusert retinal neuronal celledød hos rottefoster retinale neuronale celler, med andre ord virker indazolderivatet direkte på de retinale neuronale celler og fremviser en effekt med å beskytte retinale neuronale celler. Følgelig er indazolderivatet anvendelig for hindring eller behandling av en øyesykdom assosiert med retinal neuronal celleskade eller retinal skade.
NO20075804A 2005-04-13 2007-11-12 Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel NO20075804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005116141 2005-04-13
PCT/JP2006/307715 WO2006112313A1 (ja) 2005-04-13 2006-04-12 インダゾール誘導体を有効成分として含む網膜神経細胞保護剤

Publications (1)

Publication Number Publication Date
NO20075804L true NO20075804L (no) 2008-01-09

Family

ID=37115037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075804A NO20075804L (no) 2005-04-13 2007-11-12 Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel

Country Status (9)

Country Link
US (1) US8252945B2 (no)
EP (1) EP1870099A4 (no)
JP (1) JPWO2006112313A1 (no)
KR (1) KR20070119726A (no)
CN (1) CN101160128B (no)
CA (1) CA2604956A1 (no)
NO (1) NO20075804L (no)
RU (1) RU2392938C2 (no)
WO (1) WO2006112313A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
AU2010203425B2 (en) 2009-01-09 2015-04-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
TW201202214A (en) * 2010-05-27 2012-01-16 Santen Pharmaceutical Co Ltd Novel indazole derivative or salt thereof, production intermediate thereof, and prophylactic or therapeutic agent for chorioretinal degeneratire disease using the same
TWI476188B (zh) * 2010-05-27 2015-03-11 Ube Industries 新穎吲唑衍生物或其鹽及其製造中間體、以及使用其之抗氧化劑
JP2013530250A (ja) 2010-07-13 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二環式ピリミジン化合物
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2651949B1 (en) 2010-12-16 2015-07-15 Bayer Intellectual Property GmbH Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
US10347667B2 (en) * 2017-07-26 2019-07-09 International Business Machines Corporation Thin-film negative differential resistance and neuronal circuit

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4822820A (en) * 1986-11-24 1989-04-18 Alcon Laboratories, Inc. Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
EP1224934A3 (en) 1988-09-06 2003-03-26 Pharmacia AB Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
JP3625946B2 (ja) 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JP4004109B2 (ja) 1996-09-17 2007-11-07 参天製薬株式会社 含フッ素プロスタグランジン誘導体および医薬
JPH10259179A (ja) 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
JP4372905B2 (ja) 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
WO2001056606A1 (fr) 2000-01-31 2001-08-09 Santen Pharmaceutical Co., Ltd. Remedes pour troubles ophtalmiques
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
KR100788226B1 (ko) 2000-03-24 2007-12-26 수캄포 아게 15-케토-프로스타글란딘 또는 이의 유도체를 포함하는세포자연사 억제 조성물
AU2001286210A1 (en) 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
JP2002293771A (ja) 2001-03-30 2002-10-09 Asahi Glass Co Ltd 新規なエーテル型ジフルオロプロスタグランジン誘導体またはその塩
CN100411686C (zh) * 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
EP1410808A4 (en) 2001-07-02 2009-07-29 Santen Pharmaceutical Co Ltd MEDIUM FOR THE PROTECTION OF THE SEHNERV WITH ALPHA 1 RECEPTOR BLOCKER AS AN ACTIVE SUBSTANCE
JP2003146904A (ja) 2001-11-08 2003-05-21 Nippon Shinyaku Co Ltd 緑内障治療薬
JP2003321442A (ja) 2002-04-24 2003-11-11 Santen Pharmaceut Co Ltd 新規なジフルオロプロスタグランジンアミド誘導体
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CA2542609C (en) * 2003-10-15 2013-06-04 Ube Industries, Ltd. Novel indazole derivatives

Also Published As

Publication number Publication date
EP1870099A4 (en) 2008-07-16
US8252945B2 (en) 2012-08-28
RU2007141887A (ru) 2009-05-20
WO2006112313A1 (ja) 2006-10-26
RU2392938C2 (ru) 2010-06-27
EP1870099A1 (en) 2007-12-26
CN101160128A (zh) 2008-04-09
CA2604956A1 (en) 2006-10-26
KR20070119726A (ko) 2007-12-20
US20090012123A1 (en) 2009-01-08
CN101160128B (zh) 2010-08-18
JPWO2006112313A1 (ja) 2008-12-11

Similar Documents

Publication Publication Date Title
NO20075804L (no) Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel
NO20075464L (no) Protektivt middel for retinal nervecelle som inneholder prostaglandin F2alfaderivat som aktiv ingrediens
TW200631605A (en) Ophthalmic compositions and methods for treating eyes
BRPI0520014A2 (pt) emulsões oftálmicas estáveis de óleo-em-água com hialuronato de sódio para alìvio de olho seco
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
NO20075149L (no) Fremgangsmate til a redusere mikrobiell kontaminasjon
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AR062046A1 (es) Soluciones oftalmicas
NO20072654L (no) Cancer behandling
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
NI200800261A (es) Tratamientos de alergia ocular
RS52942B (en) TREATMENT OF TYPE 2 DIABETES BY THE COMBINATION OF DPIV IHIBITORS AND METFORMIN OR THIAZOLIDINDION
DK1968571T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater som neuroprotektive midler
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
DE602005006669D1 (de) Vorrichtung zum Schutz eines Gewebes am chirurgischen Zugang
PE20130952A1 (es) Montaje de desgaste
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
CA2634419C (en) Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
WO2006055970A3 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
NO20074850L (no) Oftalmologiske sammensetninger og anvendelse derav
WO2003061519A3 (en) Methods and compositions for preserving the viability of photoreceptor cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application